Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
JCO Precis Oncol. 2020 Oct 30:4:PO.20.00096.
doi: 10.1200/PO.20.00096.
eCollection 2020.